Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma
NCT03748134Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Dec 2018
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Innovent Biologics. Started Dec 2018; status: completed.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03748134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748134.